spacer
home > ict > spring 2019 > the patient data paradigm
PUBLICATIONS
International Clinical Trials

The Patient Data Paradigm

Translational research, multifaceted collaboration, and nextgeneration trial designs are helping to progress the reality of precision medicine in cancer treatment. Patient data − in particular, genomic data and pharmacogenomic data − have become the centre point of research. However, unless we remember to view patient contribution in medical research with the patient’s interest at heart, we may risk failing in the attempt to implement precious patient data effectively.

Cancer therapy has seen one of the most revolutionary transformations in decades. A deeper understanding of the disease at a molecular level has shifted the cancer treatment paradigm, and personalised cancer medicines are now promising to deliver the right drug to the right person at the right time, tackling tumour behaviour with precise mechanisms of action.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Aldo Poli has over 30 years’ experience in the pharma industry, with a deep expertise in methodology and statistics. He is co-founder and CEO of OPIS, a full service CRO founded in 1998 that focuses on clinical trial management for multicountry Phase 1-4 trials, non-interventional studies, and medical device investigations.
spacer
Dr Aldo Poli
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Avacta and Cytiva collaborating on COVID-19 rapid test

Cambridge and Wetherby, UK, 08 April 2020: Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has entered into a collaboration with Cytiva, formerly known as GE Healthcare Life Sciences. The companies will develop and manufacture an Affimer-based point-of-care rapid test intended for screening of large populations to diagnose the COVID-19 coronavirus infection.
More info >>

White Papers

The Role of the CRO in Effective Risk-Based Monitoring

Medpace

The clinical trial industry is evolving. In an effort to improve participant safety and data integrity, regulators are encouraging trial sponsors to transition from a focused on-site monitoring approach they have traditionally employed toward a risk-based approach that utilizes a combination of centralized and on-site monitoring techniques to ensure patient safety and data quality. The Risk-Based Monitoring (RBM) paradigm has many potential advantages over established monitoring practices including enhanced patient safety and data integrity, more efficient and effective protocol design, reduced costs, and the ability to strategically adjust oversight in keeping with changes in risk level.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement